---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-22-001774"
form_type: "8-K"
ticker: "CRVS"
cik: "0001626971"
company_name: "Corvus Pharmaceuticals, Inc."
filed_at: "2022-03-10T23:59:59+00:00"
generated_at: "2026-06-26T23:59:21.373848+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Corvus reports Q4 net loss of $9.2M, cash $69.5M; plans Phase 2 trials in NSCLC and RCC

## Summary
- Net loss Q4 2021 $9.2M vs net income $27.3M in Q4 2020 (incl $37.5M deconsolidation gain).
- Full year 2021 net loss $43.2M vs $6.0M in 2020; R&D expenses $29.1M down from $31.8M.
- Cash, equivalents and securities $69.5M at Dec 31, 2021, up from $44.3M; FY2022 cash burn guidance $34-36M.
- Plans randomized Phase 2 trial of mupadolimab plus chemo in front-line NSCLC (150 patients).
- Plans Phase 2 trial of ciforadenant plus ipilimumab/nivolumab in front-line RCC with Kidney Cancer Consortium.

## SEC filing metadata
- accession: 0001171843-22-001774
- form_type: 8-K
- ticker: CRVS
- cik: 0001626971
- company_name: Corvus Pharmaceuticals, Inc.
- filed_at: 2022-03-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1626971/000117184322001774/0001171843-22-001774-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1626971/000117184322001774/f8k_031022.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-22-001774
- JSON: https://secwatch.observer/filing/0001171843-22-001774.json
- Plain text: https://secwatch.observer/filing/0001171843-22-001774.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.